Desmoplakin (DSP) Cardiomyopathy is a genetic disorder characterized by a distinct form of ACM and a certain form of dilated cardiomyopathy.
Desmoplakin (DSP) Cardiomyopathy is a genetic disorder characterized by a distinct form of ACM and a certain form of dilated cardiomyopathy, which is caused by mutations in the Desmoplakin or DSP protein. DSP is a structural protein critical for force transmission in heart muscle.
Unlike many forms of ACM that predominantly affect the right side of the heart, DSP cardiomyopathy frequently affects the left side of the heart. The exact prevalence of DSP cardiomyopathy is unknown but may be as high as 4% of all inherited dilated cardiomyopathies and 4% of ACM, impacting up to 35,000 individuals in the US.
LX2021 is a gene therapy candidate we are developing to deliver functional Cx43 protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death including ACM and certain forms of dilated cardiomyopathy.
Cx43 is an integral protein component of gap junctions, and functionally allows small molecules and ions to flow directly between cells to allow for electrical synchronization of muscle contraction. In patients with heart disease, including heart failure, Cx43 is often relocalized in the lateral walls of myocardial cells. As a result, it is significantly reduced at cardiac muscle cell junctions, especially in ACM populations.
Restoring Cx43 protein to cardiac muscle cell-cell junctions can potentially treat multiple genetic causes of ACM because the cardiac loss of Cx43 is a molecular deficit generally observed in all ACM patient populations.